Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lamivudine | 11 | 2012 | 24 | 1.320 |
Why?
|
| Antiviral Agents | 9 | 2013 | 211 | 1.140 |
Why?
|
| Hepatitis B, Chronic | 9 | 2008 | 19 | 1.130 |
Why?
|
| Hepatitis C, Chronic | 7 | 2014 | 86 | 1.010 |
Why?
|
| Hepatitis B e Antigens | 7 | 2008 | 7 | 0.660 |
Why?
|
| Interferon-alpha | 2 | 2013 | 46 | 0.520 |
Why?
|
| Organophosphonates | 3 | 2012 | 16 | 0.500 |
Why?
|
| Adenine | 3 | 2012 | 46 | 0.490 |
Why?
|
| Valine | 1 | 2013 | 43 | 0.470 |
Why?
|
| Ribavirin | 1 | 2013 | 27 | 0.470 |
Why?
|
| Carbamates | 1 | 2013 | 41 | 0.470 |
Why?
|
| Hepacivirus | 1 | 2013 | 90 | 0.450 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 149 | 0.440 |
Why?
|
| Reverse Transcriptase Inhibitors | 7 | 2005 | 28 | 0.400 |
Why?
|
| Liver Cirrhosis | 6 | 2016 | 301 | 0.360 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 2005 | 9 | 0.330 |
Why?
|
| DNA, Viral | 9 | 2008 | 114 | 0.320 |
Why?
|
| Collagen Type III | 2 | 2016 | 21 | 0.280 |
Why?
|
| Biomarkers | 4 | 2016 | 1593 | 0.270 |
Why?
|
| Alanine Transaminase | 8 | 2008 | 137 | 0.260 |
Why?
|
| Drug Therapy, Combination | 5 | 2013 | 648 | 0.260 |
Why?
|
| Hepatitis B virus | 8 | 2005 | 23 | 0.250 |
Why?
|
| Oxazoles | 2 | 2016 | 17 | 0.240 |
Why?
|
| Tyrosine | 2 | 2016 | 196 | 0.220 |
Why?
|
| Interleukins | 3 | 2012 | 79 | 0.220 |
Why?
|
| Genotype | 4 | 2013 | 785 | 0.210 |
Why?
|
| Liver | 4 | 2014 | 1118 | 0.180 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 742 | 0.150 |
Why?
|
| Adult | 14 | 2014 | 21375 | 0.130 |
Why?
|
| Middle Aged | 13 | 2016 | 21119 | 0.130 |
Why?
|
| Interferons | 4 | 2012 | 36 | 0.130 |
Why?
|
| Double-Blind Method | 4 | 2013 | 1737 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2012 | 627 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 567 | 0.120 |
Why?
|
| Puerto Rico | 1 | 2013 | 24 | 0.120 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2013 | 16 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2013 | 7028 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2013 | 93 | 0.120 |
Why?
|
| Cholesterol, LDL | 2 | 2012 | 161 | 0.110 |
Why?
|
| Viral Load | 1 | 2013 | 127 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2013 | 289 | 0.110 |
Why?
|
| Male | 15 | 2016 | 37281 | 0.110 |
Why?
|
| Aged | 8 | 2013 | 14842 | 0.110 |
Why?
|
| Fibrosis | 1 | 2014 | 371 | 0.110 |
Why?
|
| Apolipoproteins E | 1 | 2012 | 92 | 0.110 |
Why?
|
| Mutation | 3 | 2008 | 1213 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2012 | 81 | 0.110 |
Why?
|
| Female | 14 | 2016 | 38015 | 0.100 |
Why?
|
| Humans | 19 | 2016 | 68525 | 0.100 |
Why?
|
| Fatty Liver | 1 | 2011 | 97 | 0.090 |
Why?
|
| Phenotype | 1 | 2013 | 946 | 0.090 |
Why?
|
| Hepatitis B | 2 | 2008 | 42 | 0.090 |
Why?
|
| Cytokines | 1 | 2014 | 866 | 0.090 |
Why?
|
| PPAR gamma | 1 | 2010 | 95 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2014 | 2356 | 0.070 |
Why?
|
| Adolescent | 5 | 2008 | 8903 | 0.070 |
Why?
|
| Hepatitis B Antibodies | 2 | 2004 | 8 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 507 | 0.060 |
Why?
|
| United States | 2 | 2013 | 7335 | 0.050 |
Why?
|
| Placebos | 1 | 2002 | 195 | 0.050 |
Why?
|
| Biopsy | 2 | 2014 | 539 | 0.050 |
Why?
|
| Time Factors | 2 | 2005 | 4655 | 0.040 |
Why?
|
| Quinazolines | 1 | 2016 | 70 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2016 | 76 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1465 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 1037 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 43 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2014 | 149 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2014 | 144 | 0.030 |
Why?
|
| Hong Kong | 1 | 2012 | 11 | 0.030 |
Why?
|
| Tablets | 1 | 2012 | 19 | 0.030 |
Why?
|
| Therapeutic Equivalency | 1 | 2012 | 21 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 48 | 0.030 |
Why?
|
| Capsules | 1 | 2012 | 18 | 0.030 |
Why?
|
| Half-Life | 1 | 2012 | 96 | 0.030 |
Why?
|
| Biological Availability | 1 | 2012 | 79 | 0.030 |
Why?
|
| Apolipoprotein C-I | 1 | 2012 | 2 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2012 | 29 | 0.030 |
Why?
|
| Patient Selection | 1 | 2016 | 592 | 0.030 |
Why?
|
| Safety | 2 | 2003 | 145 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2012 | 238 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 260 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2012 | 304 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2012 | 411 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1046 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2012 | 98 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2011 | 161 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2010 | 103 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 186 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 2093 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 785 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2004 | 3185 | 0.020 |
Why?
|
| Drug Resistance, Viral | 1 | 2003 | 14 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 77 | 0.010 |
Why?
|
| Retreatment | 1 | 2003 | 59 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2004 | 149 | 0.010 |
Why?
|
| Necrosis | 1 | 2003 | 239 | 0.010 |
Why?
|
| Child | 2 | 2004 | 6400 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2003 | 220 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 5708 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1054 | 0.010 |
Why?
|
| Logistic Models | 1 | 2002 | 1419 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 3256 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2003 | 3702 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2003 | 7264 | 0.010 |
Why?
|